Article
Chemistry, Multidisciplinary
Jiabin Xu, Hong Liu, Tao Wang, Zhenfu Wen, Haolin Chen, Zeyu Yang, Liyan Li, Shan Yu, Siyong Gao, Le Yang, Kan Li, Jingyuan Li, Xiang Li, Lixin Liu, Guiqing Liao, Yongming Chen, Yujie Liang
Summary: Immunotherapy, particularly dendritic cell (DC) vaccines, has shown promise in treating head and neck squamous cell carcinoma (HNSCC). However, the low immunogenicity and poor lymph node (LN) targeting efficiency have hindered the therapeutic efficacy. To overcome these limitations, a hybrid nanovaccine (Hy-M-Exo) was developed by combining tumor-derived exosome (TEX) and dendritic cell membrane vesicle (DCMV). The Hy-M-Exo nanovaccine displayed enhanced LN targeting efficiency and activated antigen presenting cells (APCs), resulting in a robust T-cell response. In a mouse model of HNSCC, the Hy-M-Exo nanovaccine demonstrated significant therapeutic efficacy, making it a promising strategy for antitumor immunotherapy.
Review
Biochemistry & Molecular Biology
Yu-Chieh Su, Wei-Chang Lee, Chih-Chun Wang, Shyh-An Yeh, Wen-Hui Chen, Po-Jen Chen
Summary: This review discusses the oncogenic significance of PI3K/AKT/mTOR signaling in HNSCC radiotherapy resistance and highlights the therapeutic potential of small molecule inhibitors against this pathway for radiosensitization in HNSCC treatment. It provides a mechanistic framework for the development of new drugs for radiosensitization in HNSCC radiotherapy via targeting the PI3K/AKT/mTOR signaling pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Libo Wang, Kejun Chen, Siyuan Weng, Hui Xu, Yuqing Ren, Quan Cheng, Peng Luo, Jian Zhang, Zaoqu Liu, Xinwei Han
Summary: This study investigates the role of PI3K pathway mutation in clinical prognosis prediction and its relationship with the immune microenvironment and response rate to immunotherapy in head and neck squamous cell carcinoma (HNSC) patients. The results show that PI3K pathway mutation predicts prolonged overall survival and better immunotherapy outcomes. The mutation group exhibits higher tumor mutation burden, activated immune-related pathways, and richer abundance of immune cells and immunomodulators.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Moran Amit, Chuan Liu, Jobran Mansour, Frederico O. Gleber-Netto, Samantha Tam, Erez N. Baruch, Mohamed Aashiq, Adel K. El-Naggar, Amy C. Moreno, David I. Rosenthal, Bonnie S. Glisson, Renata Ferrarotto, Michael K. Wong, Kenneth Tsai, Elsa R. Flores, Michael R. Migden, Deborah A. Silverman, Goujun Li, Anshu Khanna, Ryan P. Goepfert, Priyadharsini Nagarajan, Randal S. Weber, Jeffrey N. Myers, Neil D. Gross
Summary: The study showed that elective neck dissection (END) did not improve survival rates for patients with cutaneous squamous cell carcinoma (cSCC) of the head and neck and no evidence of regional metastasis. Further research is needed to clarify the role of END in patients with advanced disease.
Article
Biochemistry & Molecular Biology
Ming-Huei Chou, Hui-Ching Chuang, Yu-Tsai Lin, Ming-Hsien Tsai, Ying-Hsien Kao, I-Chun Lin, Tai-Lin Huang, Fu-Min Fang, Chih-Yen Chien
Summary: Advanced head and neck squamous cell carcinoma (HNSCC) patients have poor prognosis, but molecular targeted therapy, particularly targeting the mTOR pathway, shows promise as an effective treatment strategy. In this study, docetaxel was found to significantly inhibit HNSCC cell proliferation and migration via the PI3K/mTOR/CCL-20 signaling pathway. Additionally, mTOR inhibitors demonstrated dose-dependent inhibition of HNSCC cell growth and migration, showing synergistic effects when combined with docetaxel.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Sindhu Nair, James A. Bonner, Markus Bredel
Summary: EGFR is overexpressed in head and neck squamous cell carcinoma and anti-EGFR strategies have shown some clinical benefit but often lead to resistance. Mutations in various domains of the EGFR gene can impact drug binding, radiation response, and overall survival in HNSCC patients. Understanding the EGFR mutational landscape and its effects on treatment resistance can help stratify patients for targeted therapies and maximize therapeutic benefits.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Toxicology
L. B. Alves, A. C. Moura, J. Amorim dos Santos, G. A. Borges, E. N. S. Guerra
Summary: This systematic review investigated the effects of PI3K inhibitors on HNSCC in vitro and in vivo. The results showed reduced cell proliferation and enhanced apoptosis after treatment with PI3K inhibitors. Combination therapy with PI3K inhibitors and other drugs had a stronger anticancer effect compared to single-drug treatments. These findings support the potential use of PI3K inhibitors in clinical trials for HNSCC.
TOXICOLOGY IN VITRO
(2023)
Review
Oncology
Soudeh Ghafouri-Fard, Ali Noie Alamdari, Yashar Noee Alamdari, Atefe Abak, Bashdar Mahmud Hussen, Mohammad Taheri, Elena Jamali
Summary: This review summarizes the crucial role of the PI3K/AKT pathway in the development of squamous cell carcinomas, its impact on patient survival, the effectiveness of targeted therapies against this pathway, and the potential diagnostic markers for different types of SCCs.
CANCER CELL INTERNATIONAL
(2022)
Article
Otorhinolaryngology
Erin R. Cohen, Carly Misztal, Cortney Dable, Carmen Gomez-Fernandez, Rita G. Bhatia, Patrick Roth, Ruixuan Ma, Samuel Trosman, Carlos Green, Elizabeth Nicolli, Christine T. Dinh, Zoukaa B. Sargi
Summary: Perineural invasion (PNI) in head and neck cutaneous squamous cell carcinoma (HNcSCC) has a negative impact on disease-specific survival. Facial weakness and positive margins are high-risk factors for histopathologic PNI, while multiple nerve involvement and advanced tumor stage are associated with worse survival.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY
(2022)
Review
Biochemistry & Molecular Biology
Xin Zhou, Xiaoshen Wang
Summary: This review provides a detailed illustration of the biology, genomic features, and immune landscapes of HPV-associated HNSCC, supporting the synergistic effect of radioimmunotherapy. Current evidence and ongoing clinical trials suggest the potential of radioimmunotherapy in recurrent/metastatic or definitive settings. Future challenges include optimization of radiotherapy and the incorporation of novel therapeutic options.
Review
Medicine, General & Internal
Kamila Romanowska, Agnieszka Sobecka, Agnieszka A. Rawluszko-Wieczorek, Wiktoria M. Suchorska, Wojciech Golusinski
Summary: Head and neck squamous carcinoma (HNSCC) is the sixth most prevalent cancer worldwide, with molecular pathogenesis involving cell cycle disorders, intercellular signaling, proliferation, squamous cell differentiation, and apoptosis. In addition to genetic mutations, epigenetic alterations such as DNA methylation and histone modifications play a key role in promoting cancer formation and progression, making them potential biomarkers and therapeutic targets for HNSCC.
Article
Oncology
Kayla R. Getz, Emily Bellile, Katie R. Zarins, Cailey Rullman, Steven B. Chinn, Jeremy M. G. Taylor, Laura S. Rozek, Gregory T. Wolf, Alison M. Mondul
Summary: The study identified a significant inverse association between statin use and overall death, disease-specific death, and recurrence in untreated HNSCC patients. This protective effect was particularly pronounced in patients with HPV-positive disease.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Health Care Sciences & Services
Wenmei Jiang, Yudong Li, Ruiyu Li, Wenkuan Chen, Ming Song, Quan Zhang, Shuwei Chen
Summary: This study aimed to investigate the clinical significance of FOXD1 in head and neck squamous cell carcinoma (HNSCC). The results showed that FOXD1 expression was closely associated with postoperative recurrence and patients with high FOXD1 expression had poorer prognoses. Multivariate analysis revealed that FOXD1 was an independent prognostic factor for overall survival and disease-free survival in HNSCC patients.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Oncology
Su Il Kim, Seon Rang Woo, Joo Kyung Noh, Min Kyeong Lee, Young Chan Lee, Jung Woo Lee, Moonkyoo Kong, Seong-Gyu Ko, Young-Gyu Eun
Summary: This study examined the clinical significance of cancer stem cell (CSC) biomarker genes in head and neck squamous cell carcinoma (HNSCC) and found that the CSC gene expression signature is associated with the prognosis of HNSCC. It may help in personalized treatments, especially in cases with HPV (-) status.
Review
Oncology
Antoine Desilets, Denis Soulieres
Summary: The PI3K pathway is abnormally activated in head and neck squamous cell carcinomas, making it a valuable target for targeted therapy. Multiple PI3K inhibitors have been studied but have shown unfavorable risk-benefit ratios in unselected patient populations. Buparlisib, a potent pan-class I PI3K inhibitor, has shown promising efficacy when combined with paclitaxel for advanced head and neck squamous cell carcinoma. Results of the phase III BURAN trial are pending.